First Generic Generess Launched in US

Article

Mylan has launched the first generic version of the chewable contraceptive.

Mylan today announced the US launch of the first generic version of Warner Chilcott's chewable, low-dose contraceptive, Generess Fe.

One year ago, Actavis agreed to grant Mylan a license to market its generic version of Generess Fe under its pending Abbreviated New Drug Application (ANDA) beginning on April 1, 2015. Mylan’s partner, Famy Care Ltd, has received FDA approval for the ANDA, which was awarded 180 days of marketing exclusivity, and Mylan has immediately begun shipping the norethindrone 0.8 mg, ethinyl estradiol 0.025 mg, and ferrous fumarate 75 mg tablets.

The oral contraceptive had total US sales of approximately $114.7 million in 2014, according to IMS Health.

In addition to preventing pregnancy, the chewable tablets can give women a shorter, lighter, and predictable menstrual cycle.

Some of the most serious side effects associated with Generess Fe include blood clot, stroke, and heart attack, though more common side effects include nausea, headaches, depression, acne, and increased weight.

Some herbal remedies, such as St. John’s Wart, are known to reduce the effectiveness of the drug. Therefore, patients are advised to speak with their health care professionals before taking Generess Fe or its generic version.

Related Videos
Patient suffering from atopic dermatitis -- Image credit: Nikkikii | stock.adobe.com
Image credit: Fabio Balbi | stock.adobe.com
Image credit: Melita - stock.adobe.com
Atopic dermatitis on a patient's hand -- Image credit: Ольга Тернавская | stock.adobe.com
cropped view of man performing chest compression on dummy during cpr training class - Image credit: LIGHTFIELD STUDIOS | stock.adobe.com
Medicine law concept. Judges gavel with pills | Image Credit: Iren Moroz - stock.adobe.com
Image credit: New Africa | stock.adobe.com
biosimilar word or concept represented by wooden letter tiles on a wooden table with glasses and a book | Image Credit: lexiconimages - stock.adobe.com
© 2024 MJH Life Sciences

All rights reserved.